Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
N/A
N/A
49 Years
N/A
49 Years
Not Enrolling
Both
Leukemia, Non Hodgkin's Lymphoma, Aplastic Anemia
Both
Leukemia, Non Hodgkin's Lymphoma, Aplastic Anemia
Trial Information
Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
Inclusion Criteria
- Patients with acute leukemia, lymphoma that failed to respond or relapsed after
chemotherapy or CML beyond first chronic phase.
- Patients with aplastic anemia or myelodysplasia which failed to respond to primary
therapy are eligible.
- Patients with low grade lymphoma or CLL will only be eligible if they failed two
chemotherapy regimens and have stage IV disease.
- Patients must be
- Patients should have adequate hepatic and renal function with a bilirubin of less
than or equal to 1.5mg%, SGPT less than or equal to 3x the upper limits of normal,
and creatine less than or equal to 1.5mg%.
- Patients with serious intercurrent medical illness are not eligible.
- Patients and their donors must provide written informed consent.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
DM96-122
NCT ID:
NCT00038779
Start Date:
August 1996
Completion Date:
September 2004
Related Keywords:
- Leukemia
- Non Hodgkin's Lymphoma
- Aplastic Anemia
- Lymphoma
- CML
- CLL
- AML
- ALL
- MDS
- AA
- Anemia
- Anemia, Aplastic
- Leukemia
- Lymphoma
- Lymphoma, Non-Hodgkin
- Pancytopenia
- Hematologic Neoplasms
Name | Location |
|---|---|
| MD Anderson Cancer Center | Houston, Texas 77030-4096 |
